Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

ProMIS Neurosciences Inc. - Common Shares (NQ:PMN)

11.05 +0.41 (+3.90%)
Streaming Delayed Price Updated: 1:15 PM EDT, Sep 30, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 10,355
Open 10.68
Bid (Size) 10.82 (100)
Ask (Size) 11.29 (200)
Prev. Close 10.64
Today's Range 10.42 - 11.32
52wk Range 6.270 - 27.40
Shares Outstanding 32,689,190
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
ProMIS Neurosciences to Participate in Upcoming Conferences and Events in September
From ProMIS Neurosciences Inc.
Via GlobeNewswire
News headline image
Promis Neurosciences Q2 Earnings Call Highlights ↗
Promis Neurosciences (NASDAQ:PMN) reported second-quarter 2026 results and highlighted blinded six-month interim data from its Phase 1b PRECISE-AD study of PMN310, an investigational antibody for early... 
Via MarketBeat
Topics Earnings

Performance

YTD
+54.9%
+54.9%
1 Month
-15.4%
-15.4%
3 Month
-16.0%
-16.0%
6 Month
-13.0%
-13.0%
1 Year
+0.5%
+0.5%

More News

Read More
News headline image
ProMIS Neurosciences Reports Q2 2026 Results: Full Earnings Call Transcript ↗
Via Benzinga
Topics Earnings
News headline image
ProMIS Neurosciences Announces Second Quarter 2026 Financial Results and Provides Corporate Highlights
From ProMIS Neurosciences Inc.
Via GlobeNewswire
News headline image
ProMIS Neurosciences to Report Second Quarter 2026 Financial Results and Business Update on August 13, 2026
From ProMIS Neurosciences Inc.
Via GlobeNewswire
News headline image
Promis Reports No ARIA-E in PMN310 Alzheimer’s Trial Interim Data ↗
Via MarketBeat
News headline image
ProMIS Neurosciences Reports Positive Blinded Six-Month Interim Safety and Biomarker Data for PMN310 in the PRECISE-AD Phase 1b Alzheimer’s Disease Trial
From ProMIS Neurosciences Inc.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Monday's After-Market Session ↗
Via Benzinga
News headline image
ProMIS Neurosciences to Host Webinar to Discuss Upcoming 6-Month Blinded Interim Data from PRECISE-AD Phase 1b Trial of PMN310 in Alzheimer’s Disease
From ProMIS Neurosciences Inc.
Via GlobeNewswire
News headline image
ProMIS Neurosciences Reports First Human Evidence of Amyloid-Beta Oligomer Target Engagement by PMN310 at AAIC 2026
From ProMIS Neurosciences Inc.
Via GlobeNewswire
News headline image
ProMIS Neurosciences to Participate in Upcoming Conferences in June
From ProMIS Neurosciences Inc.
Via GlobeNewswire
News headline image
ProMIS Neurosciences Announces First Quarter 2026 Financial Results and Provides Corporate Highlights
From ProMIS Neurosciences Inc.
Via GlobeNewswire
News headline image
ProMIS Neurosciences Announces Full Year 2025 Financial Results and Provides Corporate Highlights
From ProMIS Neurosciences Inc.
Via GlobeNewswire
News headline image
ProMIS Neurosciences to Present Data on ALS & Parkinsons Disease Programs at Alzheimer’s Disease/Parkinson’s Disease 2026 International Conference (AD/PD™)
From ProMIS Neurosciences Inc.
Via GlobeNewswire
News headline image
ProMIS Neurosciences to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026
From ProMIS Neurosciences Inc.
Via GlobeNewswire
There are notable gap-ups and gap-downs in today's session. ↗
Via Chartmill
Which stocks are moving before the opening bell on Friday? ↗
Via Chartmill
News headline image
ProMIS Neurosciences Announces Up to $175 Million Private Placement Financing
From ProMIS Neurosciences Inc.
Via GlobeNewswire
News headline image
ProMIS Neurosciences Exceeds Target Enrollment in PRECISE-AD Phase 1b Clinical Trial of PMN310 in Alzheimer’s Disease
From ProMIS Neurosciences Inc.
Via GlobeNewswire
News headline image
ProMIS Neurosciences Announces New Peer-Reviewed Publication Highlighting Selective Targeting of Toxic Oligomers for Potential Clinical Benefit and Reduced ARIA Risk
From ProMIS Neurosciences Inc.
Via GlobeNewswire
News headline image
ProMIS Neurosciences Announces New Peer-Reviewed Publication Showing Plasma pTau as a Predictive Early Endpoint in Alzheimer’s trials, Supporting its Ongoing Phase 1b PRECISE-AD trial with PMN310
From ProMIS Neurosciences Inc.
Via GlobeNewswire
News headline image
ProMIS Neurosciences to Participate in the 8th Annual Evercore Healthcare Conference
From ProMIS Neurosciences Inc.
Via GlobeNewswire
News headline image
Which stocks are experiencing notable movement on Monday? ↗
Via Chartmill
News headline image
Top movers in Monday's session ↗
Via Chartmill
News headline image
The market is filled with gapping stocks in Monday's session. ↗
Via Chartmill

Frequently Asked Questions

Is ProMIS Neurosciences Inc. - Common Shares publicly traded?
Yes, ProMIS Neurosciences Inc. - Common Shares is publicly traded.
What exchange does ProMIS Neurosciences Inc. - Common Shares trade on?
ProMIS Neurosciences Inc. - Common Shares trades on the Nasdaq Stock Market
What is the ticker symbol for ProMIS Neurosciences Inc. - Common Shares?
The ticker symbol for ProMIS Neurosciences Inc. - Common Shares is PMN on the Nasdaq Stock Market
What is the current price of ProMIS Neurosciences Inc. - Common Shares?
The current price of ProMIS Neurosciences Inc. - Common Shares is 11.05
When was ProMIS Neurosciences Inc. - Common Shares last traded?
The last trade of ProMIS Neurosciences Inc. - Common Shares was at 09/30/26 01:15 PM ET
What is the market capitalization of ProMIS Neurosciences Inc. - Common Shares?
The market capitalization of ProMIS Neurosciences Inc. - Common Shares is 361.38M
How many shares of ProMIS Neurosciences Inc. - Common Shares are outstanding?
ProMIS Neurosciences Inc. - Common Shares has 361M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.